Ftse Mib
36.148,73
-0,33%
DAX
20.918,53
0,10%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
108.222,00
4,95%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ EyePoint Pharmaceuticals Inc (EYPT) EyePoint Pharmaceuticals Inc (EYPT) Notizie

EYPT

EyePoint Pharmaceuticals (EYPT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYPT
DataOraFonteTitoloSimboloCompagnia
16/01/202513:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
13/01/202513:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
13/01/202513:00GlobeNewswire Inc.EyePoint Provides Company Update and Anticipated Development Milestones for 2025NASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/01/202522:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/01/202522:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/01/202513:00GlobeNewswire Inc.EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
17/12/202413:00GlobeNewswire Inc.EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202413:00GlobeNewswire Inc.EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
14/11/202421:10Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/11/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/11/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/11/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/10/202421:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
30/10/202421:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
30/10/202402:47GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
28/10/202422:14GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
28/10/202412:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
24/10/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
22/10/202421:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/09/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of DirectorsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
19/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/08/202422:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/08/202422:42Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/08/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/08/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
26/06/202414:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
18/06/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/06/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/05/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
06/05/202413:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EYPT

La tua Cronologia

BIT
ENEL
Enel
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
BAMI
Banco BPM
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
BPE
Bper Banca
BIT
SRG
Snam
BIT
SPM
Saipem
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network